Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

Rare Earths Stocks: 9 Biggest Companies in 2024

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

When is the Starlink IPO Date and Can You Invest? (Updated 2024)

Investing in Graphene Companies (Updated 2024)

Trending Press Releases

SAGA Metals Reports Channel Sample Assay Results at Double Mer Uranium Project

Radiopharm achieves Nasdaq listing of ADS

HyProMag USA Feasibility Study Demonstrates Robust Economics and the Opportunity to Develop a Major New, Domestic Source of Recycled Rare Earths Magnets for the United States

Extension of Option to Acquire Major Nickel Asset

Trillion Energy Successfully Re-completes Wells in VS Program

FPX Nickel Leverages Strong Balance Sheet and Intends to Launch Normal Course Issuer Bid

More Press Releases
Trending Companies

Purpose Bitcoin ETF

BTCC:CA

Soma Gold Corp.

SOMA:CA

MP Materials Corp.

MP:US

First Helium

HELI:CA
More Companies
Trending Reports

2024 Gold Outlook Report

2024 Uranium Outlook

2024 Lithium Market Outlook

2024 Uranium Outlook: Australia Edition

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Sonnet BioTherapeutics Holdings Inc.

NASDAQ:SONN
Press Releases

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Interactive Chart

×